Improving performance through comparison

1
Improving performance through comparison
2
BioPharma is being driven towards Operational
Excellenceand Innovation
1
!
Strengthening regulatory requirements
Increased international competition
Demanding customer service requirements
Aggressive biogenerics industry
Customer pressure on price and margin
Shortening product life-cycles
Rapid technology advance
Global sourcing options
Scarce people skills and resources
Maturing outsourcing opportunities
Increased RD cost and lead time
3
BioBenchmark 2007objectives
2

• Enabling you to drive improvements by providing
  information to identify operational gaps, target
  opportunities, and prioritize action plans
• Creating a perspective on the status of the
  BioPharma sector through a qualitative and
  quantitative baseline of operational performance
  across companies and countries
• The study will be the reference point to
• Identify the position of a company relative to
  the industry
• Provide insight into best practice - and how it
  is achieved
• Set goals for specific operational improvement
• Build a roadmap for targeted improvements

?
4
3
_at_

• The BioBenchmark was initiated by requests from
  Biopharma Operations Excellence Consortium
  members and Tefens customers. It was completed
  at the end of 2003, and reports issued March 2004
• For large companies - provided a snap-shot of how
  they were performing vs. their peers, and showed
  improvement opportunities
• For smaller companies - provided a roadmap for
  the design of world-class systems
• Identified projects and goals for specific
  operational areas

Feedback from previous participants
5
BioPharma has moved on, BioBenchmark 2007 is
needed
4

• Existing clients and BioPharma Operational
  Excellence Consortium members have expressed the
  desire to repeat the BioBenchmark
• The industry has changed a great deal in recent
  years, and has diversified in terms of activities
  and locations. A comprehensive benchmark study is
  required to provide a clear overall picture of
  the current industry status
• Tefen has the unique expertise and contacts to
  carry this out successfully for the benefit of
  all concerned

6
5

Current invitees and past participants include
leading global BioPharma companies
7
Four main deliverables
6

• A customized report for each participant, showing
  their data against the performance of their peers
• A facilitated workshop with company Executives to
  develop an improvement roadmap
• A report on the BioPharma Industrys vision,
  challenges and trends
• A complete listing of all questions and answers
  from all participants (anonymous, but with own
  answers identified)

8
7
Future direction and trends
?
Operational Objectives
A structured approach
Qualitative
Quantitative
Enabling Practices
Basic Facts
QA
Operations
QC
9
8
Future direction and trends Impact of
BioGenerics/BioSimilars New product
introduction Outsourcing (upstream /
downstream) Inbound supply chain Facility
location Production planning strategy Titre /
yield Organisation Human resources Staff
productivity Quality systems
Operational Objectives Quality Cycle
time Service reliability Staff turnover
utilisation Equipment utilisation Supplier
relationships Innovation
?
Example topics and benchmark measures covered
Enabling Practices Staff organisation Staff
flexibility Quality mindset Clarity of
communications Performance appraisal
development Organisation of work areas Measures
to maximise equipment utilisation Effective
scheduling planning Level of process
automation Process performance information Working
practices driven by cycle times Document workflow
Basic Facts Space Equipment People Inventory/WIP
Ways of working Throughput activity
10
9
?
Example questions
11
Company commitment and benefits
10

?
Company commitment
Agree to participate, sign non-disclosure
agreement
Support Tefen on-site to complete and check
benchmark data
Meet Tefen if required, provide contacts,
allocate time
Complete initial data and survey requirements
Clarify or revise any outstanding data
5 days
3 days
1 day
Company outcomes
A customized report for each participant, showing
their data against the performance of their peers
A complete listing of all questions and answers
from all participants (anonymous, but with own
answers identified)
A report on the BioPharma Industrys vision,
challenges and trends
A facilitated workshop with company Executives to
develop an improvement roadmap

12
11
Contact biobm2007_at_tefen.com

or Marc Puich Partner Tefen 1065 E. Hillsdale
Blvd, Suite 421Foster City CA 94404-1615 USA Tel
 1 650 357 1120 Mobile [phone]
mpuich_at_tefen.com
or John Glass Associate Director Tefen Cavendish
Court 11-15 Wigmore Street London W1U 1PF United
Kingdom Tel [phone] Mobile [phone]
2149 johng_at_tefen.co.uk
How can I be included?
13
Tefensexpertise
12

• Tefen is a publicly traded, international
  management and operations consulting firm, which
  brings over 20 years of experience, serving some
  of the worlds leading corporations.
• Tefen designs and implements innovative strategic
  and operational solutions that improve
  bottom-line performance through increased
  productivity, optimised business processes,
  enhanced customer service and quality assurance.
• Seven offices across Europe, USA and Israel.
• 300 full-time professional staff.
• We have successfully worked with over 40 of the
  top 50 global Life Sciences businesses, including
  8 of the top 10 BioPharma companies.
• Tefen facilitates the BioPharma Operations
  Excellence Consortium and completed the first
  ever comprehensive BioBenchmarktm study in 2004

?